Merit Medical plans to commercially launch the device next year in the US. Credit: Michael Vi/Shutterstock.

Merit Medical Systems has received premarket approval from the US Food and Drug Administration (FDA) for its WRAPSODY Cell-Impermeable Endoprosthesis allowing the company to commercially launch the device next year in the US.

Engineered to maintain long-term vessel patency, which is vital for patients undergoing dialysis treatments, the device is a response to the critical need for maintaining adequate blood flow through arteriovenous (AV) fistula and AV graft sites in individuals with dialysis.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Merit researchers developed the device in 2010 in partnership with interventional radiologist Dr Bart Dolmatch at Palo Alto Medical Foundation.

The device features a nitinol stent frame and a multi-layered polytetrafluoroethylene (PTFE) covering, including an inner-luminal layer to decrease platelet and fibrin formation and a cell-impermeable layer to avert migration of the tissue.

Dolmatch said: “Preserving vascular access for dialysis patients is critical for them to maintain lifesaving treatment.

“I believe the advancements that the WRAPSODY device offers will translate to better outcomes for haemodialysis patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The nitinol frame is tailored to offer radial force, softened ends, and compression resistance to ensure the device conforms to vessels withstands physiological compression, and minimises stress on vessel walls.

Clinical trial outcomes from the WRAPSODY WAVE pivotal trial demonstrated that subjects with AV fistula and AV graft treated with the device for dialysis outflow lesions achieved a target lesion primary patency of 89.8% and 82%, at a six-month period, respectively.

Merit Medical Systems chairman and CEO Fred Lampropoulos said: “Over the past decade, Merit has worked to ensure that the WRAPSODY device helps physicians achieve the best possible outcomes for patients.”

The company reported the six-month data from the WAVE trial in September this year.

Moreover, the primary patency of the entire access circuit at six months was 72.6% for AV fistula patients and 68.8% for those with an AV graft.